EMD Serono and Opexa amend agreement to support ongoing development of Tcelna for multiple sclerosis
EMD Serono and Opexa Amend Agreement to Support Ongoing Development of Tcelna (imilecleucel-T) for Multiple Sclerosis Personalized [...]
Pfizer Inc. and Synthon, an international pharmaceutical company specializing in the development of complex generic medicines, today [...]
A statement from our CMSC leadership: While the implications for MS patient care may need to be re-evaluated and changed in the future [...]
Multiple Sclerosis Coalition Applauds Passage of 21st Century Cures Act Inclusion of data-gathering provision is vital to future MS [...]
Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus interferon beta-1a (Rebif®) in Two Phase [...]
Multiple Sclerosis Coalition Announces New Board President Lisa Taylor Skutnik elected to lead coalition of MS nonprofits Cherry [...]
Sandoz announces US launch of Glatopa™, the first generic competitor to Copaxone® 20mg Glatopa is the first FDA-approved, [...]
Novartis Statement on Reported Case of PML Novartis has been informed of a patient with progressive multifocal leukoencephalopathy [...]
FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS BLA Acceptance Follows [...]
Mallinckrodt Research Fellowship Award Program Announcement Mallinckrodt Pharmaceuticals is pleased to announce the Research Fellowship [...]